NASDAQ: ACHV
Achieve Life Sciences Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their ACHV stock forecasts and price targets.

Forecast return on equity

Is ACHV forecast to generate an efficient return?

Company
907.7%
Industry
140.91%
Market
90.47%
ACHV's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ACHV forecast to generate an efficient return on assets?

Company
341.04%
Industry
32.45%
ACHV is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ACHV earnings per share forecast

What is ACHV's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$1.23
Avg 2 year Forecast
-$1.10
Avg 3 year Forecast
$0.45

ACHV revenue forecast

What is ACHV's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$20.1M
Avg 2 year Forecast
$101.8M
Avg 3 year Forecast
$240.0M

ACHV vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ACHV$3.25N/AN/A
BYSI$2.79N/AN/A
THTX$2.48N/AN/A
SGMO$0.49$4.50+816.50%Buy
CTNM$4.43$22.50+407.90%Strong Buy

Achieve Life Sciences Stock Forecast FAQ

What is ACHV's earnings growth forecast for 2025-2027?

(NASDAQ: ACHV) Achieve Life Sciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Achieve Life Sciences's earnings in 2025 is -$46,160,000.On average, 2 Wall Street analysts forecast ACHV's earnings for 2025 to be -$42,489,213, with the lowest ACHV earnings forecast at -$46,477,996, and the highest ACHV earnings forecast at -$38,500,430. On average, 2 Wall Street analysts forecast ACHV's earnings for 2026 to be -$37,980,154, with the lowest ACHV earnings forecast at -$38,847,281, and the highest ACHV earnings forecast at -$37,113,027.

In 2027, ACHV is forecast to generate $15,434,857 in earnings, with the lowest earnings forecast at $6,937,014 and the highest earnings forecast at $23,932,700.

If you're new to stock investing, here's how to buy Achieve Life Sciences stock.

What is ACHV's revenue growth forecast for 2026-2028?

(NASDAQ: ACHV) Achieve Life Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Achieve Life Sciences's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast ACHV's revenue for 2026 to be $695,435,694, with the lowest ACHV revenue forecast at $693,701,440, and the highest ACHV revenue forecast at $697,169,947. On average, 2 Wall Street analysts forecast ACHV's revenue for 2027 to be $3,530,940,330, with the lowest ACHV revenue forecast at $3,468,507,200, and the highest ACHV revenue forecast at $3,593,373,459.

In 2028, ACHV is forecast to generate $8,324,417,280 in revenue, with the lowest revenue forecast at $8,324,417,280 and the highest revenue forecast at $8,324,417,280.

What is ACHV's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ACHV) forecast ROA is 341.04%, which is higher than the forecast US Biotechnology industry average of 32.45%.

What is ACHV's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ACHV) Achieve Life Sciences's current Earnings Per Share (EPS) is -$1.34. On average, analysts forecast that ACHV's EPS will be -$1.23 for 2025, with the lowest EPS forecast at -$1.34, and the highest EPS forecast at -$1.11. On average, analysts forecast that ACHV's EPS will be -$1.10 for 2026, with the lowest EPS forecast at -$1.12, and the highest EPS forecast at -$1.07. In 2027, ACHV's EPS is forecast to hit $0.45 (min: $0.20, max: $0.69).

What is ACHV's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ACHV) forecast ROE is 907.7%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.